Moderna (MRNA) said late Friday it filed an application with the US Food and Drug Administration for review of its Spikevax formula targeting SARS-CoV-2 variant LP.8.1.
The application is based on FDA guidance updating COVID-19 vaccines to a monovalent JN.1 lineage, with a preference for the LP.8.1.
The most common adverse reactions were headache, fatigue, myalgia, chills, arthralgia, axillary swelling, nausea, and fever.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。